FindTrial
Sign In

Phase II study of concurrent chemotherapy with itraconazole in advanced gynecologic tumors.

Phase II study of concurrent chemotherapy with itraconazole in advanced gynecologic tumors. - P2 trial of itraconazole

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000013951
Enrollment
16
Registered
2014-05-20
Start date
2014-05-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecologic cancer

Interventions

itraconazole with chemotherapy

Sponsors

Department of Obstetrics and Gynecology, Hyogo College of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. advanced or metastatic sarcoma 2. symptomatic or radiological recurrence within 6 months after last platinum administration of ovarian, fallopian, peritoneal, endometrial, and/or cervical cancers.

Exclusion criteria

Exclusion criteria: history of gemecitabine or docetaxel

Design outcomes

Primary

MeasureTime frame
PFS, Response rate, OS, AEs, QOL, molecular profiling—

Countries

Japan

Contacts

Public ContactHiroshi Tsubamoto

Hyogo College of Medicine Department of Obstetrics and Gynecology

tsuba@hyo-med.ac.jp+81-798-45-6481

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026